UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): March 16, 2020
CYREN
LTD.
(Exact
Name of Registrant as Specified in its Charter)
|
Israel
|
|
000–26495
|
|
Not
applicable
|
|
(State
or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
|
10
Ha-Menofim St., 5th Floor
Herzliya,
Israel
|
|
4672561
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
011–972–9–863–6888
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
|
Trading
symbol(s)
|
|
Name
of exchange on which registered
|
|
Ordinary
Shares, par value ILS 0.15 per share
|
|
CYRN
|
|
Nasdaq
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
☐
|
Emerging
growth company
|
|
☐
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
Item
1.01 Entry into a Material Definitive Agreement.
Securities
Purchase Agreements
On March 16, 2020, Cyren Ltd. entered
into Securities Purchase Agreements, or the Purchase Agreements, with certain purchasers named therein, or the Purchasers, pursuant
to which we agreed to sell and issue $10.25 million aggregate principal amount of our 5.75% Convertible Debentures due March 2024,
or the Debentures, referred to herein as the Financing, which includes the purchase by Brett Jackson, our Chief Executive Officer,
of a Debenture in the principal amount of $250,000 pursuant to a Purchase Agreement. The Purchase Agreements contain customary
representations, warranties, covenants, closing conditions, and indemnification of the Purchasers by us. We are required to pay
certain liquidated damages to the Purchasers in the event we fail to satisfy the current public information requirements of Rule
144 under the Securities Act of 1933, as amended, or the Securities Act, until such time that satisfaction of such requirements
is no longer required for the sale of ordinary shares underlying the Debentures pursuant to Rule 144.
Craig-Hallum Capital Group LLC, or the
Placement Agent, acted as placement agent in connection with the Financing. We have agreed to pay the Placement Agent an aggregate
cash fee equal to 6% of the aggregate gross proceeds from the Financing plus reimbursement of certain expenses not to exceed $60,000
in the aggregate.
Pursuant to the Purchase Agreements, subject
to certain exempt issuances set forth in the Purchase Agreements, we and all of our subsidiaries are prohibited from issuing any
ordinary shares for ninety days after the date of the Purchase Agreements and from entering into an agreement involving variable
rate transactions (as defined in the Purchase Agreements).
The Debentures will be guaranteed on an
unsecured basis by certain existing and future subsidiaries. The Debentures rank junior in right of payment to our convertible
notes due December 2021. The Debentures will have an initial conversion price of $0.75 per share, subject to adjustments, provided
that the conversion price for the Debenture purchased by Mr. Jackson cannot be less than $0.73 per share. Interest on the Debentures
will be payable semi-annually in cash or, subject to the satisfaction of certain equity conditions set forth in the Debentures,
in ordinary shares at a rate of 5.75% per annum, calculated on the basis of a 360-day year, and will accrue daily until payment
in full of the outstanding principal, together with all accrued and unpaid interest. We must pay late fees at a rate of the lesser
of 18% per annum or the maximum rate permitted by law on overdue accrued and unpaid interest.
Registration
Rights Agreement
In
connection with the Financing, on March 16, 2020, we entered into a Registration Rights Agreement with the Purchasers, or the
Registration Rights Agreement. Pursuant to the Registration Rights Agreement, we agreed to (i) file one or more registration statements
with the Securities and Exchange Commission, or the SEC, within sixty days of the date of the Registration Rights Agreement to
cover the resale of the shares of our ordinary shares that are issuable to the Purchasers upon any conversion of the Debentures
or as interest payments, or the Shares, (ii) use our best efforts to have all such registration statements declared effective
within the time frames set forth in the Registration Rights Agreement, and (iii) use our best efforts to keep such registration
statements effective during the time frames set forth in the Registration Rights Agreement. In the event that such registration
statements are not declared effective within the timeframes set forth in the Registration Rights Agreement, any such effective
registration statements subsequently become unavailable, or use of the prospectus contained in such registration statements is
suspended for certain periods of time, we would be required to pay certain liquidated damages to the Purchasers.
Item
2.02 Results of Operations and Financial Condition.
To
the extent the information in Item 7.01 or Exhibit 99.2 relates to a completed fiscal period, such information is incorporated
by reference into this Item 2.02.
Item
3.02 Unregistered Sales of Equity Securities.
The
information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02.
We
will issue and sell the Debentures, and the ordinary shares to be issued upon conversion or to be paid as interest, in reliance
on the exemption from the registration requirements of the Securities Act by virtue of Section 4(a)(2) thereof and Rule 506 of
Regulation D thereunder. In connection with the Purchasers’ execution of the Purchase Agreements, the Purchasers represented
to us that they are each an “accredited investor” as defined in Regulation D of the Securities Act and that the Debentures
to be purchased by them will be acquired solely for their own account and for investment purposes and not with a view to the future
sale or distribution.
The
issuance and sale of the Debentures have not been, and such securities will not be, registered under the Securities Act or the
securities laws of any other jurisdiction, and such securities may not be offered or sold in the United States absent registration
or an applicable exemption from registration requirements. This Current Report on Form 8-K does not constitute an offer to sell,
or a solicitation of an offer to buy, any security and shall not constitute an offer, solicitation or sale in any jurisdiction
in which such offering would be unlawful.
Item
7.01 Regulation FD Disclosure.
On
March 16, 2020, we issued a press release announcing the Financing and the entry into the Purchase Agreements and the Registration
Rights Agreements. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
In
connection with the Financing, we disseminated an investor presentation to potential investors relating to the Financing. A copy
of the investor presentation is attached hereto as Exhibit 99.2.
The
information furnished under this Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The
information shall not be deemed incorporated by reference into any other filing with the SEC made by us, regardless of any general
incorporation language in such filing.
Item
9.01 Financial Statements and Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
|
CYREN
LTD.
|
|
|
|
|
|
|
Dated:
|
March
17, 2020
|
By:
|
/s/
J. Michael Myshrall
|
|
|
|
Name:
|
J. Michael Myshrall
|
|
|
|
Title:
|
Chief
Executive Officer
|
3
Exhibit 99.1
PRESS
RELEASE
Cyren
Announces Private Placement of Convertible Debentures
McLean,
VA – March 17, 2020 – Cyren (NASDAQ: CYRN) announced today that it has entered into purchase agreements with a
select group of accredited and institutional investors for the purchase of $10.25 million aggregate principal amount of convertible
debentures in a private placement.
The
debentures will be unsecured, subordinated obligations of Cyren and carry a 5.75% interest rate per annum, payable semi-annually
in cash or ordinary shares at Cyren's election. The debentures will have a four year term and mature in March 2024, unless converted
in accordance with their terms prior to maturity. The debentures have a conversion price of $0.75 per share and are convertible
into 1,333 ordinary shares per $1,000 principal amount of debentures. The converion price is subject to adjustment based on the
price and timing of future equity offerings and other customary adjustments. Upon the satisfaction of price and other conditions,
Cyren has the right to force the conversion of the debentures.
Cyren
expects to use the proceeds of the offering for general corporate purposes. The closing of the sale of the debentures is expected
to occur on or about March 19, 2020, subject to the satisfaction of customary conditions and approvals.
The
debentures and the ordinary shares, if any, issuable upon conversion of the debentures or payable as interest on the debentures
have not been registered under the Securities Act of 1933, as amended, or any state securities laws and may not be offered or
sold in the United States absent registration with the U.S. Securities and Exchange Commission, or SEC, or an applicable exemption
from such registration requirements. Pursuant to a registration rights agreement, Cyren has agreed to file a registration statement
with the SEC registering the resale of the ordinary shares underlying the debentures.
Craig-Hallum
Capital Group is acting as exclusive placement agent in connection with this transaction.
This
press release is neither an offer to sell nor a solicitation of an offer to buy these securities and shall not constitute an offer,
solicitation or sale in any state or jurisdiction in which such offer, solicitation or sale would be unlawful.
This
press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. For example, statements in the future tense, and statements including words such as
"expect," "plan," "estimate," "anticipate," or "believe" are forward-looking
statements. These statements are based on information available at the time of the press release and Cyren assumes no obligation
to update any of them. The statements in this press release are not guarantees of future performance and actual results could
differ materially from current expectations as a result of numerous factors, including uncertainties as to the ability to successfully
complete the offering in accordance with its terms and in accordance with the expected schedule, the possibility that various
closing conditions for the offering may not be satisfied or waived, as well as those risks described in Cyren’s reports
filed with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2018 and subsequent quarterly reports
and reports on Form 8-K, which are available through www.sec.gov.
About
Cyren
More
than 1.3 billion users around the world rely on Cyren's 100% cloud security solutions to protect them against cyberattacks and
data loss every day. Powered by the world's largest security cloud, Cyren (NASDAQ: CYRN) delivers fast time-to-protection with
award-winning email security, cloud sandboxing and DNS filtering services for business, and threat intelligence solutions for
service providers and security vendors like Microsoft, Google and Check Point. Learn more at www.cyren.com.
Blog: blog.cyren.com
Facebook: www.facebook.com/CyrenWeb
LinkedIn: www.linkedin.com/company/cyren
Twitter: www.twitter.com/CyrenInc
Company
Contact:
Mike
Myshrall, CFO
Cyren
+1.703.760.3320
mike.myshrall@cyren.com
